Death and Dying in Heart Failure With Normal Ejection Fraction

Shueh Yiang Lim; Roger Mark Beadle; Michael Frenneaux

doi:10.1016/j.amjcard.2009.06.050

Death and Dying in Heart Failure With Normal Ejection Fraction

Shueh Yiang Lim, Roger Mark Beadle, Michael Frenneaux

Research output: Contribution to journal › Editorial › peer-review

5 Citations (Scopus)

Abstract

The overall mortality rate in patients with heart failure with normal ejection fraction (HFNEF) appears to be comparable to that in patients with heart failure with reduced ejection fraction. In contrast to the latter group of patients, randomized trials with neurohumoral blockade in patients with HFNEF have failed to demonstrate reduction in mortality. This is at least in part related to the lower proportion of heart failure-related death in the overall population of patients with HFNEF. In conclusion, better characterization of patients with HFNEF at greatest risk for heart failure-related death and understanding the risks of the different modes of death would allow more effective use of specific heart failure medical or device therapy in patients with HFNEF. (C) 2009 Elsevier Inc. All rights reserved. (Am, J Cardiol 2009;104:1311-1314)

Original language	English
Pages (from-to)	1311-1314
Number of pages	4
Journal	The American Journal of Cardiology
Volume	104
Issue number	9
DOIs	https://doi.org/10.1016/j.amjcard.2009.06.050
Publication status	Published - 1 Nov 2009

Keywords

society-of-cardiology
mortality
trial
prognosis
echocardiography
prevalence
morbidity
mode
HF

Access to Document

10.1016/j.amjcard.2009.06.050

Cite this

@article{60eb60b9813346e3868c45ddefee689e,

title = "Death and Dying in Heart Failure With Normal Ejection Fraction",

abstract = "The overall mortality rate in patients with heart failure with normal ejection fraction (HFNEF) appears to be comparable to that in patients with heart failure with reduced ejection fraction. In contrast to the latter group of patients, randomized trials with neurohumoral blockade in patients with HFNEF have failed to demonstrate reduction in mortality. This is at least in part related to the lower proportion of heart failure-related death in the overall population of patients with HFNEF. In conclusion, better characterization of patients with HFNEF at greatest risk for heart failure-related death and understanding the risks of the different modes of death would allow more effective use of specific heart failure medical or device therapy in patients with HFNEF. (C) 2009 Elsevier Inc. All rights reserved. (Am, J Cardiol 2009;104:1311-1314)",

keywords = "society-of-cardiology, mortality, trial, prognosis, echocardiography, prevalence, morbidity, mode, HF",

author = "Lim, {Shueh Yiang} and Beadle, {Roger Mark} and Michael Frenneaux",

year = "2009",

month = nov,

day = "1",

doi = "10.1016/j.amjcard.2009.06.050",

language = "English",

volume = "104",

pages = "1311--1314",

journal = "The American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - Death and Dying in Heart Failure With Normal Ejection Fraction

AU - Lim, Shueh Yiang

AU - Beadle, Roger Mark

AU - Frenneaux, Michael

PY - 2009/11/1

Y1 - 2009/11/1

N2 - The overall mortality rate in patients with heart failure with normal ejection fraction (HFNEF) appears to be comparable to that in patients with heart failure with reduced ejection fraction. In contrast to the latter group of patients, randomized trials with neurohumoral blockade in patients with HFNEF have failed to demonstrate reduction in mortality. This is at least in part related to the lower proportion of heart failure-related death in the overall population of patients with HFNEF. In conclusion, better characterization of patients with HFNEF at greatest risk for heart failure-related death and understanding the risks of the different modes of death would allow more effective use of specific heart failure medical or device therapy in patients with HFNEF. (C) 2009 Elsevier Inc. All rights reserved. (Am, J Cardiol 2009;104:1311-1314)

AB - The overall mortality rate in patients with heart failure with normal ejection fraction (HFNEF) appears to be comparable to that in patients with heart failure with reduced ejection fraction. In contrast to the latter group of patients, randomized trials with neurohumoral blockade in patients with HFNEF have failed to demonstrate reduction in mortality. This is at least in part related to the lower proportion of heart failure-related death in the overall population of patients with HFNEF. In conclusion, better characterization of patients with HFNEF at greatest risk for heart failure-related death and understanding the risks of the different modes of death would allow more effective use of specific heart failure medical or device therapy in patients with HFNEF. (C) 2009 Elsevier Inc. All rights reserved. (Am, J Cardiol 2009;104:1311-1314)

KW - society-of-cardiology

KW - mortality

KW - trial

KW - prognosis

KW - echocardiography

KW - prevalence

KW - morbidity

KW - mode

KW - HF

U2 - 10.1016/j.amjcard.2009.06.050

DO - 10.1016/j.amjcard.2009.06.050

M3 - Editorial

SN - 0002-9149

VL - 104

SP - 1311

EP - 1314

JO - The American Journal of Cardiology

JF - The American Journal of Cardiology

IS - 9

ER -

Death and Dying in Heart Failure With Normal Ejection Fraction

Abstract

Keywords

Access to Document

Fingerprint

Cite this